Companies › Therini Bio
2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology, Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| THN391 Intravitreal injection (mechanism not specified) | – | Phase 1 | Diabetic Macular Edema | Mar 2027 |
| THN391 | – | Phase 1 | Alzheimer Disease, Early Onset | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06701721 | THN391 | Phase 1 | Diabetic Macular Edema | Ophthalmology | Mar 2027 |
| NCT06814730 | THN391 | Phase 1 | Alzheimer Disease, Early Onset | Neurology | Mar 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.